Applied Biochemistry and Biotechnology

, Volume 184, Issue 4, pp 1319–1331 | Cite as

A Catalyst from Burkholderia cenocepacia for Efficient Anti-Prelog’s Bioreduction of 3,5-Bis(Trifluoromethyl) Acetophenone

  • Songzhu Yu
  • Hongxia Li
  • Yan Lu
  • Guojun Zheng


(R)-3, 5-Bis(trifluoromethyl)phenyl ethanol is a key chiral intermediate for the synthesis of aprepitant. Through a genome mining approach, an NADPH-dependent short-chain dehydrogenases derived from Burkholderia cenocepacia (Bc-SDR) was discovered with excellent anti-Prelog’s stereoselectivity of reducing 3, 5-bis(trifluoromethyl) acetophenone. The enzyme with 247 amino acids was successfully expressed in Escherichia coli and the molecular weight was about 26 kDa. Optimization of reaction conditions showed that the optimum temperature and pH of the enzyme was 25 °C and pH 7.0, respectively. Strong enhancement of enzyme activity was observed in the presence of 1 mM Mn2+. In addition, Bc-SDR exhibited (R)-selective enantioselectivity toward acetophenone derivatives, which makes it a potential catalyst for obtaining aromatic chiral alcohols as useful blocks in pharmaceutical applications.


3, 5-Bis(trifluoromethyl) acetophenone Carbonyl reductase Anti-Prelog’s Burkholderia cenocepacia Aprepitant 


Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

Supplementary material

12010_2017_2628_MOESM1_ESM.docx (8.9 mb)
ESM 1 Fig. S1 Multiple sequence alignment of the target sequence (NCBI Reference Sequence: ANZ75577.1, ANZ77886.1, ANZ77893.1, XP_002489352.1, XP_002492297.1, XP_002493760.1, XP_002494195.1, WP_006481546.1, WP_006481604.1, WP_006481801.1, WP_006483065.1, WP_006485075.1, WP_006485158.1, WP_006488202.1, WP_012336650.1, WP_012492403.1, WP_050013528.1, WP_058903664.1, WP_060214413.1, WP_077189930.1) with the template sequence (Leifsonia xyli HS0904) Fig. S2 Sequence alignment of the target sequence (Burkholderia cenocepacia) with the template sequence (Leifsonia xyli HS0904). (DOCX 9094 kb)


  1. 1.
    Moore, J. C., Pollard, D. J., & Kosjek, B. (2007). Advances in the enzymatic reduction of ketones. Accounts of Chemical Research, 40, 1412–1419.CrossRefGoogle Scholar
  2. 2.
    Bornscheuer, U. T., Huisman, G. W., & Kazlauskas, R. J. (2012). Engineering the third wave of biocatalysis. Nature, 485, 185–194.CrossRefGoogle Scholar
  3. 3.
    Huisman, G. W., Liang, J., & Krebber, A. (2010). Practical chiral alcohol manufacture using ketoreductases. Current Opinion in Chemical Biology, 14, 122–129.CrossRefGoogle Scholar
  4. 4.
    Noey, E. L., Tibrewal, N., & Jiménez-Osés, G. (2015). Origins of stereoselectivity in evolved ketoreductases. Proceedings of the National Academy of Sciences, 112, E7065–E7072.Google Scholar
  5. 5.
    Wang, P., Cai, J. B., & Ouyang, Q. (2011). Asymmetric biocatalytic reduction of 3,5-bis (trifluoromethyl) acetophenone to (1R)-[3,5-bis (trifluoromethyl) phenyl] ethanol using whole cells of newly isolated Leifsonia xyli HS0904. Applied Microbiology and Biotechnology, 90, 1897–1904.CrossRefGoogle Scholar
  6. 6.
    Gelo-Pujic, M., Le Guyader, F., & Schlama, T. (2006). Microbial and homogenous asymmetric catalysis in the reduction of 1-[3,5-bis (trifluoromethyl) phenyl] ethanone. Tetrahedron: Asymmetry, 17, 2000–2005.CrossRefGoogle Scholar
  7. 7.
    Brands, K. M. J., Payack, J. F., & Rosen, J. D. (2003). Efficient synthesis of NK1 receptor antagonist aprepitant using a crystallization-induced diastereoselective transformation. Journal of the American Chemical Society, 125, 2129–2135.CrossRefGoogle Scholar
  8. 8.
    Nakade, S., Ohno, T., & Kitagawa, J. (2008). Population pharmacokinetics of aprepitant and dexamethasone in the prevention of chemotherapy-induced nausea and vomiting. Cancer Chemotherapy and Pharmacology, 63, 75–83.CrossRefGoogle Scholar
  9. 9.
    Kurbanoglu, E. B., Zilbeyaz, K., & Taskin, M. (2009). Total production of (R)-3, 5-bistrifluoromethylphenyl ethanol by asymmetric reduction of 3,5-bis (trifluoromethyl)-acetophenone in the submerged culture of Penicillium expansum isolate. Tetrahedron: Asymmetry, 20, 2759–2763.CrossRefGoogle Scholar
  10. 10.
    Gai, P., Tang, C., Liu, J., Liu, Y., Zhang, C., & Wu, Z. (2013). Asymmetric anti-Prelog reduction of 3,5-bis(trifluoromethyl)-acetophenone by microbacterium oxydans C3. Chinese Journal of Applied & Environmental Biology, 19, 37–42.CrossRefGoogle Scholar
  11. 11.
    Li, J., Wang, P., He, J. Y., Huang, J., & Tang, J. (2013). Efficient biocatalytic synthesis of (R)-[3,5-bis (trifluoromethyl) phenyl] ethanol by a newly isolated Trichoderma asperellum ZJPH0810 using dual cosubstrate: ethanol and glycerol. Applied Microbiology and Biotechnology, 97, 6685–6692.CrossRefGoogle Scholar
  12. 12.
    Wang, N., Huang, J., & Luo, H. (2013). Purification and characterization of a new carbonyl reductase from Leifsonia xyli HS0904 involved in stereoselective reduction of 3, 5-bis (trifluoromethyl) acetophenone. Journal of Molecular Catalysis B: Enzymatic, 92, 1–6.CrossRefGoogle Scholar
  13. 13.
    Wang, N. Q., Sun, J., & Huang, J. (2014). Cloning, expression, and directed evolution of carbonyl reductase from Leifsonia xyli HS0904 with enhanced catalytic efficiency. Applied Microbiology and Biotechnology, 98, 8591–8601.CrossRefGoogle Scholar
  14. 14.
    Liu, Y., Tang, T. X., & Pei, X. Q. (2014). Identification of ketonereductase ChKRED20 from the genome of Chryseobacterium sp. CA49 for highly efficient anti-Prelog reduction of 3,5-bis(trifluoromethyl)acetophenone. Journal of Molecular Catalysis B: Enzymatic, 102, 1–8.CrossRefGoogle Scholar
  15. 15.
    Li, H. M., Moncecchi, J., & Truppo, M. D. (2015). Development of an immobilized ketoreductase for enzymatic (R)-1-(3,5-Bis(trifluoromethyl)phenyl)ethanol production. Organic Process Research & Development, 19, 695–700.CrossRefGoogle Scholar
  16. 16.
    Chen, K., Li, K., & Deng, J. (2016). Carbonyl reductase identification and development of whole-cell biotransformation for highly efficient synthesis of (R)-[3,5-bis (trifluoromethyl) phenyl] ethanol. Microbial Cell Factories, 15, 191.CrossRefGoogle Scholar
  17. 17.
    Prelog, V. (1964). Specification of the stereospecificity of some oxido-reductases by diamond lattice sections. Pure and Applied Chemistry, 9, 119–130.CrossRefGoogle Scholar
  18. 18.
    Singh, A., Basit, A., & Banerjee, U. C. (2009). Burkholderia cenocepacia: a new biocatalyst for efficient bioreduction of ezetimibe intermediate. Journal of Industrial Microbiology & Biotechnology, 36, 1369.CrossRefGoogle Scholar
  19. 19.
    Yıldız, T. (2015). An oxazaborolidine-based catalytic method for the asymmetric synthesis of chiral allylic alcohols. Tetrahedron: Asymmetry, 26, 497–504.CrossRefGoogle Scholar
  20. 20.
    Hoffmann, F., & Maser, E. (2007). Carbonyl reductases and pluripotent hydroxysteroid dehydrogenases of the short-chain dehydrogenase/reductase superfamily. Drug Metabolism Reviews, 39, 87–144.CrossRefGoogle Scholar
  21. 21.
    Kallberg, Y., Oppermann, U., & Jörnvall, H. (2002). Short-chain dehydrogenase/ reductase (SDR) relationships: a large family with eight clusters common to human, animal, and plant genomes. Protein Science, 11, 636–641.CrossRefGoogle Scholar
  22. 22.
    Oppermann, U., Filling, C., & Hult, M. (2003). Short-chain dehydrogenases/reductases (SDR): the 2002 update. Chemico-Biological Interactions, 143, 247–253.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2017

Authors and Affiliations

  1. 1.State Key Laboratory of Chemical Resources EngineeringBeijing University of Chemical TechnologyBeijingPeople’s Republic of China

Personalised recommendations